Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tourmaline Bio

14.74
+0.20001.38%
Volume:71.82K
Turnover:1.04M
Market Cap:378.65M
PE:-4.58
High:14.79
Open:14.43
Low:13.63
Close:14.54
Loading ...

Tourmaline Bio Initiated at Outperform by LifeSci Capital

Dow Jones
·
25 Feb

Tourmaline Bio management to meet with Truist

TIPRANKS
·
20 Feb

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire
·
27 Jan

Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker

GlobeNewswire
·
10 Jan

Tourmaline Bio: Promising Cardiovascular and Innovative Indications Drive Buy Rating Amid Upcoming Data Milestones

TIPRANKS
·
08 Jan

Truist Financial Sticks to Its Buy Rating for Tourmaline Bio (TRML)

TIPRANKS
·
11 Dec 2024

Tourmaline Bio Price Target Maintained With a $49.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Dec 2024

Tourmaline Bio Updates on Clinical Progress and Outlook

TIPRANKS
·
11 Dec 2024

Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day

GlobeNewswire
·
10 Dec 2024

Tourmaline Bio to host investor day

TIPRANKS
·
09 Dec 2024

BMO Capital Initiates Tourmaline Bio at Outperform With $50 Price Target

MT Newswires Live
·
06 Dec 2024

Analysts’ Top Healthcare Picks: Neumora Therapeutics, Inc. (NMRA), Tourmaline Bio (TRML)

TIPRANKS
·
22 Nov 2024

Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024

GlobeNewswire
·
14 Nov 2024

Tourmaline Bio, Inc. Reports Third Quarter Financial Results

TIPRANKS
·
12 Nov 2024

Tourmaline Bio Inc : H.c. Wainwright Raises Target Price to $49 From $48

THOMSON REUTERS
·
12 Nov 2024

Tourmaline Bio Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
12 Nov 2024

Tourmaline Bio price target raised to $49 from $48 at H.C. Wainwright

TIPRANKS
·
12 Nov 2024

Tourmaline Bio’s Promising Clinical Developments and Financial Stability Underpin Buy Rating

TIPRANKS
·
11 Nov 2024